In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.

Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.

New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.

In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.

Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.

AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.

In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.